Observe Medical ASA · OSL:OBSRV

Observe Medical ASA — Q2 2020 Earnings Presentation

33 slides from Observe Medical ASA's earnings presentation, Aug 18, 2020

  1. Slide 1: Observe Medical Q2 and first half year 2020

    OBSERVE MEDICAL Q2 and first half year 2020 CEO Björn Larsson / CFO Per Arne Nygård Oslo, August 18, 2020

  2. Slide 2: Overview

    Overview Addressing major clinical Sippi® challenges: Hospital acquired infections Solid medtech platform Automated and wireless Quality assurance of data for growth connected digital urine meter for ICUs and wards Stressed out healthcare staff Strong market Exploit market Fully underwritten opportu

  3. Slide 3: Slide 3

  4. Slide 4: Hourly urine monitoring is the last remaining manual procedure in the ICU

    Hourly urine monitoring of patients is the last remaining manual procedure in the ICU with significant clinical implications Risk of infections Inaccurate patient data for clinical decisions Time-consuming for staff, reducing clinical capacity

  5. Slide 5: Sippi is the only automated, digital urine meter with wireless data transfer

    Sippi® is the only automated, digital urine meter with wireless data transfer (Sipplink®) to the hospital patient data management system and which detects (Sippsense®) and hinders (Sippcoat®) bacterial biofilm formation – that can lead to urinary infections

  6. Slide 6: Sippi addresses major clinical challenges for ICUs

    Sippi® addresses major clinical challenges for ICUs Clinical challenges Sippi® clinical impact Risk of infections Hindering hospital acquired infections Inaccurate patient data for Improved quality of patient clinical decisions data for clinical decisions Time-consuming for staff, Reduced time spent

  7. Slide 7: Significant market opportunity with value growth accelerated by Covid-19

    Significant market opportunity with value growth accelerated by Covid-19 Post Covid-19 outbreak market assumptions CURRENT MARKET POTENTIAL ICU CAPABILITIES VOLUME GROWTH SIPPI® SHARE OF MARKET VALUE Sippi® market opportunity ~0.5M +20-30% +100% Sippi® base units +30M Market volume Sippi® disposable

  8. Slide 8: Key focus: Exploit the market opportunity in the Nordics and Europe

    Key focus: Exploit the market opportunity in the Nordics and Europe Estimated up to 3x value growth in Europe for Sippi® post Covid-19 outbreak Strengthening the global commercial resources and team Nordics – direct sales Recruiting direct sales team Rest of Europe – distributors Strengthening and e

  9. Slide 9: Strengthened partnership for Sippi launch in Italy

    Strengthened partnership for Sippi® launch in Italy Updated distribution agreement Market size1 signed in August with SIM Italia S.r.l. for launch and distribution ~7 500 ICU beds 101 175 of Sippi® in the Italian market 1,258 722 ~450 000 admissions annually 478 – comprehensive collaboration 656 Dis

  10. Slide 10: Strengthened partnership for Sippi launch in Italy

    Strengthened partnership for Sippi® launch in Italy Updated distribution agreement Market size1 signed in August with SIM Italia S.r.l. for launch and distribution ~7 500 ICU beds 101 175 of Sippi® in the Italian market 1,258 722 ~450 000 admissions annually 478 – comprehensive collaboration 656 Dis

  11. Slide 11: Scientific article shows Sippi technology reducing microbial biofilm formation

    Newly published scientific article provides evidence of Sippi® technology reducing microbial biofilm formation – a risk factor for patient infection Slettengren M. et al, : “Making medical devices safer: impact of plastic and silicone oil on microbial biofilm formation” Journal of Hospital Infection

  12. Slide 12: Financial Review

    FINANCIAL REVIEW CFO Per Arne Nygård

  13. Slide 13: Key Figures: Profit and Loss Statement

    FINANCIAL REVIEW Key Figures Profit and Loss Statement The sales activities slowed down in the second quarter and resulted in no revenues compared to TNOK 33 in same quarter last year. Amounts in TNOK (excl. earnings per share) Q2 2020 Q2 2019 H1 2020 H1 2019 FY 2019 The increased Gross result in bo

  14. Slide 14: Statement of Financial Positions: Assets

    FINANCIAL REVIEW Statement of Financial Positions Assets Amounts in TNOK At 30 June 2020 At 30 June 2019 At 31 December 2019 ASSETS Non-current assets Goodwill (denominated in SEK) from Goodwill 33 405 29 482 30 333 acquisition of Observe Medical Intangible assets 21 976 21 317 20 997 International

  15. Slide 15: Statement of Financial Positions: Equity and Liabilities

    FINANCIAL REVIEW Statement of Financial Positions Equity and Liabilities Equity as of 30 June at MNOK 5.9 affected by Amounts in TNOK At 30 June 2020 At 30 June 2019 At 31 December 2019 negative result in the period and the share issue EQUITY AND LIABILITIES related to exercise of share options in t

  16. Slide 16: Cash Flow Statement second quarter 2020

    FINANCIAL REVIEW Cash Flow Statement second quarter 2020 (Amounts in TNOK) Negative cash flow from operations due to negative EDITDA Positive cash flow from financing 5 918 -6 965 activities mainly due to increased interest 460 bearing debt The Group has cash balance at TNOK 965 as of 30 June 2020 -

  17. Slide 17: Summary and Outlook

    SUMMARY AND OUTLOOK CEO Björn Larsson

  18. Slide 18: Summary and outlook

    Summary and outlook Summary Outlook Rights issue of NOK 45 million Executing go-to-market strategy completed Strengthening commercial Unchanged estimate of Sippi® organization and distributor market value potential network Near-time focus on Nordics and Strengthen clinical and health Europe economic

  19. Slide 19: Q&A

    Q&A

  20. Slide 20: Thank you!

    Thank you!

  21. Slide 21: Finance Calendar

    Finance Calendar 30 April 21 May 3 November Publication of Annual General Presentation of Annual report Meeting 3. quarter 2020 2020 23 February Presentation of 12 May 4. quarter 2020 Presentation of 1. quarter 2021

  22. Slide 22: Appendix

    Appendix

  23. Slide 23: Management team

    OBSERVE MEDICAL AT A GLANCE Experienced Board and management team in place Management team Björn Larsson Per Arne Nygård Emil Karheiding Kristina Adlesic Chief executive officer Chief financial officer CTO QA/RA MGR Board of directors Terje Bakken Kristin Nyberg Kathrine Gamborg Andreassen Thomas Gr

  24. Slide 24: Condensed Consolidated Statement of Comprehensive Income

    (UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2020) Condensed Consolidated Statement of Comprehensive Income Amounts in NOK Q2 2020 Q2 2019 H1 2020 H1 2019 FY 2019 Operating revenues 0 33 140 32 220 60 433 176 650 Cost of materials 61 945 506 598 121 265 544 733 636 781 Gross result -61 945 -473 458 -89 0

  25. Slide 25: Condensed Consolidated Statement of Financial Positions

    (UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2020) Condensed Consolidated Statement of Financial Positions Amounts in NOK At 30 June 2020 At 30 June 2019 At 31 December 2019 ASSETS Non-current assets Goodwill 33 404 714 29 482 117 30 333 459 Intangible assets 21 976 325 21 317 436 20 997 241 Tangible ass

  26. Slide 26: Condensed Consolidated Statement of Financial Positions

    (UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2020) Condensed Consolidated Statement of Financial Positions Amounts in NOK At 30 June 2020 At 30 June 2019 At 31 December 2019 EQUITY AND LIABILITIES Total equity 5 898 913 6 202 858 14 541 734 Non-current liabilities Non-current lease liabilities 34 394 365

  27. Slide 27: Cash Flow Statement

    Cash Flow Statement (UNAUDITED FOR THE PERIOD ENDED 30 JUNE 2020) (Amounts in NOK) H1 2020 H1 2019 Q2 2020 Q2 2019 FY 2019 Cash flow from operating activities Result before tax -10 567 034 -8 476 374 -10 143 091 -4 385 745 -16 917 301 Depreciation and impairment 1 596 875 2 138 967 818 297 1 095 612

  28. Slide 28: Top 20 Shareholders – as of August 11, 2020

    Top 20 Shareholders – as of August 11, 2020 Rank Name Number of shares % of top 20 % of total Country 1 NAVAMEDIC ASA 4 222 727 26.12 % 21.73 % Norway 2 INGERØ REITEN INV. COMPANY AS 3 939 394 24.37 % 20.27 % Norway 3 RO, LARS 1 450 000 8.97 % 7.46 % Norway 4 UBS SWITZERLAND AG 1 420 522 8.79 % 7.31

  29. Slide 29: Definitions of Alternative Performance Measures (APM)

    Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result: Operating revenues le

  30. Slide 30: Basis for Preparation

    oKeovserve Taaexe |(er=l|

  31. Slide 31: Basis of preparation and statements

    Basis of preparation and statements This presentation provides financial highlights for the second quarter and first half year for Observe Medical Group. The financial information is reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The s

  32. Slide 32: Copyright and Disclaimer

    Copyright and Disclaimer Copyright Disclaimer expressed or implied, as to the accuracy, Copyright of all published material This Presentation includes and is based, reliability or completeness of the including photographs, drawings and inter alia, on forward-looking information and Presentation, and

  33. Slide 33: oKeovserve

    oKeovserve Taaexe |(er=l|

Observe Medical — Q2 2020 Earnings Presentation on 6ix